



Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609

April 24, 2023

To the Office of the Attorney General of Vermont,

On 04/19/2023, and pursuant to 18 V.S.A. § 4637(b), Gamida Cell, Inc. ("Gamida Cell") provided to the State of Vermont new drug notice(s) for OMISIRGE® (NDC 73441-0800-04).

OMISIRGE® (omidubicel-only) became commercially available on 04/18/2023.

Gamida Cell's interpretation of the phrase "introduction of a new prescription drug to market" is to mean when the product is available for purchase.

Pursuant to 18 V.S.A. § 4637(c), and pertaining to, OMISIRGE®, Gamida Cell submits the following additional information:

**1. US and International marketing and pricing plans used at launch:**

OMISIRGE® will be promoted by our account management team to healthcare professionals to educate them on our product. We will use various means of promotion including in-office visits and through online channels such as websites. Pricing was established by performing extensive market research and analysis on our clinical and healthcare resource utilization data. Additionally, it involved years of product development investments and various operational costs.

Gamida Cell's detailed marketing or pricing plans for OMISIRGE® are not publicly available.

**2. Estimated volume of patients who may be prescribed the drug:**

The estimated number of patients that will be prescribed OMISIRGE® is approximately 2000- 2500 upon reaching peak market share.

**3. Whether the FDA granted breakthrough therapy designation or priority review:**

OMISIRGE® was granted breakthrough therapy designation and priority review.

**4. Date and price of acquisition:**

Gamida Cell, Inc. did not acquire OMISIRGE®.

If you have any further questions, please do not hesitate to contact me.

Regards,



**Rocio Manghani, MPH**

Sr. Vice President, Market Access

Direct: 858-254-7070 | [rociom@gamida-cell.com](mailto:rociom@gamida-cell.com)